FDA Warns Against Use of Expired Amazon Basic Care Levonorgestrel 1.5 mg Across Multiple Lots

Amazon Basic Care's levonorgestrel 1.5 mg product has drawn an FDA safety notification after multiple lots were confirmed delivered to purchasers past their labeled expiration dates, a distribution failure with direct implications for expiry management controls, lot traceability systems, and distributor oversight obligations under 21 CFR Part 211.

The FDA confirmed that affected products were distributed between January 24, 2025, and April 29, 2026. The agency has not identified a specific manufacturing defect but is flagging the expiry breach as a consumer safety concern, advising that any unit with a passed expiration date be disposed of immediately. Consumers who have already used the expired product are directed to consult a healthcare professional.

For QA directors and supply chain leads, the distribution window spanning more than 15 months points to a systemic gap in downstream expiry verification rather than an isolated fulfillment error. Under GMP expectations, distributors and repackagers carry responsibility for ensuring product integrity through to the point of sale, including confirmation that shelf life has not lapsed at the time of delivery. Where lot-level traceability is weak, identifying and quarantining affected units across a dispersed e-commerce fulfillment network compounds the remediation burden considerably.

Adverse events or product quality complaints linked to the affected lots should be submitted through the FDA MedWatch program, either via the online portal or by fax at 1-800-FDA-0178. Regulatory affairs leads monitoring post-market safety signals should ensure internal intake processes are aligned to capture any incoming reports tied to this product line.

The breadth of the distribution window will likely inform how FDA frames any follow-up action, including whether distributor-level corrective measures or additional lot-specific communications are required.

Source: FDA Drug Alerts and Statements via FDA.gov, May 15, 2026.